Santhera to Present Results from Phase III Study with Catena®/ Raxone® in Duchenne Muscular Dystrophy at the International Congress of the World Muscle Society Freitag, 26. September 2014 - 07:15
Liestal, Switzerland, September 26, 2014 - Santhera Pharmaceuticals (SIX: SANN) today announced that results from the Phase III (DELOS) study in Duchenne Muscular Dystrophy (DMD) will be presented at the 19th International Congress of the World Muscle Society (WMS), being held in Berlin, Germany on October 7-11, 2014. The results will be presented in a late breaking oral session by the principal investigator of the study, Prof. Gunnar Buyse of the University Hospitals, Leuven.
Presentation details:
Date: October 11, 2014
Session: Late Breaking Session (14:30-16:00h CEST)
Presenter: Prof. Gunnar Buyse MD, PhD, University Hospitals, Leuven (Belgium)
Title: Idebenone reduces loss of respiratory function in Duchenne muscular dystrophy - Outcome of a phase III double blind, randomised, placebo-controlled trial (DELOS)
The presentation will be available for download on the company's website.
Results from the DELOS study, the first ever positive outcome of a double-blind, placebo-controlled phase III trial in DMD, were initially announced in May this year. The study met its primary endpoint and demonstrated that Catena®/Raxone® can delay the loss of respiratory function in patients not taking concomitant glucocorticoid steroids. The preservation of respiratory function is considered of major clinical importance for patients with DMD.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Catena®/Raxone® as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and Primary Progressive Multiple Sclerosis (PPMS) and omigapil for Congenital Muscular Dystrophies (CMD), all areas of high unmet medical need for which no therapies are currently available. For further information, please visit the Company's website www.santhera.com.
Raxone® and Catena® are trademarks of Santhera Pharmaceuticals.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone +41 61 906 89 64
thomas.meier@santhera.com
US Investor contact
Andrew McDonald
Phone +1 646 597 6979
andrew@lifesciadvisors.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
